Systemic Anti-Cancer Therapy Regimen Library
Haematology regimens within the SACT Regimen Library currently only specify mandatory supportive care medicines to be used for all patients, unless contraindicated. A clinically equivalent mandatory medicine may be substituted as per institutional practice.
Supportive care factors are included in all regimens, with the appropriate dimensions (value) as Recommended (for most patients), Consider (for some patients after clinical risk assessment), or with guidance (e.g. emetogenicity classification or if variable). Centres are expected to include antiemetics and other supportive care medicines within their own prescribing systems.
Published
Published
Name
Version
Date
PCN MM - BMP [bortezomib, melphalan and prEDNISone] 2.0.0 29/08/2023 PCN MM - BTD [bortezomib, thalidomide and dexamethasone] induction 2.0.0 29/08/2023 PCN MM - CyBorDex High [CYCLOPHOSPHamide, bortezomib and dexamethasone] 2.0.0 29/08/2023 PCN MM - CyBorDex Low [CYCLOPHOSPHamide, bortezomib and dexamethasone] 2.0.0 29/08/2023 PCN MM - daratumumab [subcut], lenalidomide and dexamethasone 2.0.0 29/08/2023 PCN MM - ixazomib, lenalidomide and dexamethasone 2.0.0 29/08/2023 PCN MM - lenalidomide [3/1 dosing] post autologous stem cell transplant 2.0.0 29/08/2023 PCN MM - lenalidomide [continuous dosing] post autologous stem cell transplant 2.0.0 29/08/2023 PCN MM - lenalidomide and dexamethasone 1.0.0 19/09/2023 PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] consolidation 2.0.0 29/08/2023 PCN MM - LenBorDex [lenalidomide, bortezomib, and dexamethasone] induction followed by autologous stem cell transplant 2.0.0 29/08/2023 PCN MM - MP [melphalan and preDNISone] 1.0.0 19/09/2023 PCN MM - MPT [melphalan, prEDNISone and thalidomide] 1.0.0 19/09/2023 PCN MM - pamidronate 30mg Q4W 2.0.0 18/03/2024 PCN MM - pamidronate 90mg Q4W 1.0.0 18/03/2024 PCN MM - zoledronic acid [Q12W] 1.0.0 23/01/2023 PCN MM Relapsed - BTD-PACE [bortezomib, thalidomide, dexamethasone, cISplatin, DOXOrubicin, CYCLOPHOSPHamide and etoposide] 1.0.0 17/06/2024 PCN MM Relapsed - carfilzomib and dexamethasone [Q1W] 2.0.0 29/08/2023 PCN MM Relapsed - daratumumab [subcut] 2.0.0 29/08/2023 PCN MM Relapsed - daratumumab [subcut], bortezomib and dexamethasone [Q3W] followed by daratumumab [subcut] [Q4W] 2.0.0 29/08/2023 PCN MM Relapsed - LenBorDex [lenalidomide, bortezomib, and dexamethasone] Q4W 2.0.0 29/08/2023 PCN MM Relapsed - pomalidomide and dexamethasone 2.0.0 29/08/2023 PCN MM Relapsed - pomalidomide, bortezomib and dexamethasone 2.0.0 29/08/2023
IN PARTNERSHIP
